Small molecule · Inhibitor of SARS-CoV-2 3C-like protease (3CLpro) · developed by Pfizer
Phase 3Most advanced trial (none active)
1Registered trials
What is Lufotrelvir?
Lufotrelvir is a phosphate prodrug that is converted in the body to PF-00835231, an inhibitor of the coronavirus 3C-like protease. By blocking this enzyme, it prevents cleavage of viral polyproteins needed for viral replication. It is studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
PF-07304814
Drug type
Small molecule
Targets
SARS-CoV-2 3C-like protease (3CLpro)
Mechanism
Inhibitor of SARS-CoV-2 3C-like protease (3CLpro)
Pathways
viral polyprotein processing, viral RNA replication and transcription
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.